Lisata Therapeutics Acquires Marea Therapeutics

BioMarin Acquires Alesta Therapeutics

August 18, 2026

Biotechnology

BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in development and regulatory milestone payments, to obtain its lead clinical-stage asset, ALE1. The acquisition closed on September 1, 2026; Alesta had spun out its non-ALE1 assets before closing, and became a wholly owned BioMarin subsidiary.

Kuva Labs Acquires Lisata Therapeutics

March 6, 2026

Pharmaceuticals

Kuva Labs, Inc. has entered into a definitive agreement to acquire Lisata Therapeutics, Inc. for $5.00 per share in cash, plus a contingent value right (CVR) that could pay an additional $1.00 per share upon an FDA-related regulatory milestone tied to certepetide. The transaction is expected to close in the second quarter of 2026, subject to customary tender offer conditions, including tender of a majority of Lisata’s outstanding shares.

Merck & Co. (Merck Sharp & Dohme) Acquires Cidara Therapeutics

January 8, 2026

Biotechnology

Merck Sharp & Dohme LLC (Merck & Co., Inc.) completed its cash tender offer and follow-on merger to acquire Cidara Therapeutics, Inc. for $221.50 per share, valuing the deal at about $9.2 billion. The acquisition adds Cidara’s late-stage, long-acting, strain-agnostic influenza antiviral candidate CD388 to Merck’s respiratory pipeline.

Aprea Therapeutics Acquires Atrin Pharmaceuticals

May 16, 2022

Biotechnology

Aprea Therapeutics, Inc. completed a stock-for-stock acquisition of privately held Atrin Pharmaceuticals, obtaining Atrin’s DNA damage response (DDR) oncology programs and proprietary discovery platform. The transaction expands Aprea’s pipeline (including ATRN-119, ATRN-354 and ATRN-W1051), adds Atrin leadership to Aprea’s management and board, and was structured to issue a mix of common stock and Series A preferred stock to former Atrin equity holders (who will own ~58.8% pro forma on an as-converted basis).

Somatus Acquires Strategic Assets from Lumiata

April 28, 2022

Healthcare Services

Somatus has acquired strategic assets from Lumiata to integrate Lumiata's healthcare AI and predictive analytics into Somatus' RenalIQ platform, improving early identification of people with chronic kidney disease and prediction of disease progression. The deal brings Lumiata talent (including Jessica McCarthy) into Somatus and aims to strengthen care delivery, reduce costs for provider and health-plan partners, and address health inequities.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.